Sugi Predict

Sugi Predict / Compounds / SCHEMBL2199528

SCHEMBL2199528

SCHEMBL2199528

COc1ccc(Cl)c(C=O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 3/20 0.61
▸ ALDH1A1 P00352 7/20 0.58
▸ TRIM24 O15164 1/20 0.56
▸ TYR P14679 1/20 0.56
▸ TRIM33 Q9UPN9 1/20 0.56
▸ CYP1A2 P05177 4/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CYP2A6 P11509 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ NFE2L2 Q16236 3/20 0.43
▸ RELA Q04206 1/20 0.43
▸ CYP1A1 P04798 2/20 0.42
▸ CYP1B1 Q16678 2/20 0.42
▸ ABCG2 Q9UNQ0 2/20 0.42
▸ JUN P05412 1/20 0.42
▸ NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1236491 0.86 ALDH1A1 (0.66) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL18144204 0.83 RELA (0.59) ALDH1A1CYP1A2KDM4ECYP2A6LMNA
SCHEMBL18144207 0.83 RELA (0.59) ALDH1A1CYP1A2KDM4ECYP2A6LMNA
SCHEMBL19497328 0.81 MEN1 (0.47) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL12672585 0.81 ALDH1A1 (0.70) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL29957021 0.81 ALDH1A1 (0.70) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL8907495 0.80 ALDH1A1 (0.64) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL16957010 0.80 ERN1 (0.47) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL5440523 0.80 ALDH1A1 (0.43) ERN1ALDH1A1TRIM24TYRTRIM33
SCHEMBL662439 0.79 KDM4E (0.46) ERN1ALDH1A1KDM4EMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6150378-A 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY CEPHALON, INC. (US) 2000-11-21 — — US claimed
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
EP-4696681-A1 HERBICIDAL THIOCARBAMATES CARRYING AN ISOXAZOLIN-SUBSTITUTED PHENYL RING BASF SE (DE) 2026-02-18 — — EP disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
EP-4665339-A1 INHIBITING ALPHA V BETA 8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 — — EP disclosed
US-12428413-B2 Rho kinase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2025-09-30 — — US disclosed
CN-119569553-A Preparation method and application of 3-methoxy-4-chlorobenzaldehyde 苏州亚科科技股份有限公司 2025-03-07 — — CN disclosed
WO-2024183807-A1 ARYL FUSED IMIDAZOLE COMPOUND AND MEDICAL USE THEREOF 哈尔滨三联药业股份有限公司 2024-09-12 — — WO disclosed
CN-118619885-A Arylimidazole compound and medical application thereof 哈尔滨三联药业股份有限公司 2024-09-10 — — CN disclosed
WO-2024173570-A1 INHIBITING αvβ8 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2024-08-22 — — WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 — — WO disclosed
US-6288231-B1 ENZYME INHIBITORS CEPHALON, INC. 2001-09-11 — — US disclosed
US-6150378-A 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY CEPHALON, INC. (US) 2000-11-21 — — US disclosed
CN-1202159-A Pyrazin-2-one derivatives, their use, and intermediates for their production SUMITOMO CHEMICAL CO (JP) 1998-12-16 — — CN disclosed
US-4962203-A ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS MERCK FROST CANADA, INC. (CA) 1990-10-09 — — US disclosed
EP-0206751-A2 2-Substituted quinolines, their preparation and use MERCK FROSST CANADA INC. (CA) 1986-12-30 — — EP disclosed
US-4058532-A 1-Phenyl-3,4-dihydrocarbostyrils STERLING DRUG INC. (US) 1977-11-15 — — US disclosed
US-4058642-A HYPERTENSIVE BOEHRINGER INGELHEIM GMBH (DT) 1977-11-15 — — US disclosed
US-4049715-A 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols STERLING DRUG INC. (US) 1977-09-20 — — US disclosed
US-3994902-A Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds STERLING DRUG INC. (US) 1976-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428413-B2 Rho kinase inhibitors and compositions and methods of use thereof ROCK1, ROCK2, RHOA ERN1 705/4885ALDH1A1 4692/4885TRIM24 3029/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH ERN1 912/4885ALDH1A1 3178/4885TRIM24 1192/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 ERN1 1448/4885ALDH1A1 3094/4885TRIM24 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.